Seeking Alpha

Jefferies lifts it price target on Jazz Pharmaceuticals (JAZZ) to $64 from $56 on its belief...

Jefferies lifts it price target on Jazz Pharmaceuticals (JAZZ) to $64 from $56 on its belief that the firm can beat its own guidance with its reconfigured sales structure. Analysts also raise their EPS estimates for Jazz for FY12 and FY13 by $0.04 and $0.73, respectively.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)